Today's News |
Precision NanoSystems Announces 20,000 Square Foot New Corporate Headquarters
Tuesday, October 18, 2016Company Profile | Follow Company
Vancouver, BC, BC, October 18, 2016--(T-Net)--Precision NanoSystems (PNI), a biotechnology company pioneering innovative manufacturing solutions for novel nanoparticles used to investigate or treat disease, has announced the opening of its new corporate headquarters in Vancouver, British Columbia.
The custom-designed, 20,000 square foot facility fully integrates the company's functions to enhance product and service offerings to customers.
The single location houses R&D, product development, contract manufacturing, technical support, sales and marketing, and business development functions. The facility is designed to promote synergy between PNI's multidisciplinary technical and commercial teams with a focus on maximizing customer benefit from the NanoAssemblr™ product suite.
“We recently released the NanoAssemblr Spark™, Blaze™ and Scale-Up systems to provide a fully integrated product suite that enables nanoparticle manufacture from discovery to clinical development,” said James Taylor CEO of PNI. “Our new facility connects our team to ensure that we achieve our goal of supporting the accelerated development of novel nanomedicines that offer new treatment options for patients.”
“The new headquarters includes an increased wet lab to expand our contract research, development and manufacturing services,” said Euan Ramsay, COO. “We recognized that providing custom formulation and process solutions can accelerate nanomedicine development and augment the in-house capabilities of our clients, and we wanted to ensure that we designed the new facility to meet these needs.”
More information on Precision's products and services can be found at precisionnanosystems.com.
About Precision NanoSystems, Inc.
Precision NanoSystems, Inc. (PNI) creates innovative solutions for the discovery, development and manufacture of novel nanoparticles for use as medicines and in medical research. PNI's proprietary NanoAssemblr™ platform enables the rapid, reproducible, and scalable manufacture of next generation nanoparticle formulations for the targeted delivery of therapeutic and diagnostic agents to cells and tissues in the body. PNI provides instruments, reagents and services to life sciences researchers, including pharmaceutical companies, and builds strategic collaborations to revolutionize healthcare through nanotechnology. For more information, visit www.precisionnanosystems.com.
Other Recent Company News |
|||||||||||||||||||
|